<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011891</url>
  </required_header>
  <id_info>
    <org_study_id>18-5885</org_study_id>
    <nct_id>NCT04011891</nct_id>
  </id_info>
  <brief_title>Comparison of OpeN VErsus RoboTic Partial Nephrectomy</brief_title>
  <acronym>CONVERT</acronym>
  <official_title>Comparison of OpeN VErsus RoboTic Partial Nephrectomy Trial - a Feasibility Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized controlled feasibility trial for patients undergoing partial
      nephrectomy for T1 renal masses at Princess Margaret. Participants will be randomized receive
      either open or robotic partial nephrectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, unblinded RCT where a total of 30 patients who have consented to
      undergo partial nephrectomy for a T1 renal mass under the care of a uro-oncologist at
      Princess Margaret Cancer Centre will be randomized 1:1 to one of two arms:

      Arm A: Robotic Partial Nephrectomy Arm B: Open Partial Nephrectomy

      Patients will complete all pre-admission testing as per standard of care, regardless of arm
      allocation. Creatinine and eGFR are measured routinely pre-operatively and these values will
      be used as a baseline for all patients. In addition to standard pre-admission testing,
      participants will complete the European Organization for the Research and Treatment of Cancer
      Quality of Life Questionnaire (EORTC QLQ-C30) offered either on paper at the visit or online
      via an emailed link.

      Following either open or robotic partial nephrectomy, participants will be followed as per
      standard of care. Generally, this includes follow-up at 4-6 weeks, 6 months, 12 months and
      then either every 6 months thereafter or yearly, depending on pathology. All clinical outcome
      measures for this study are routinely reported post-operatively and in the follow-up period
      for partial nephrectomy patients. Quality of life will be assessed at the 4-7 week and 6
      month follow-up visits using the EORTC QLQ-C30 offered either on paper at the visit or online
      via an emailed link. Participants will also be asked to complete a Surgical Recovery/Flank
      Bulge questionnaire regarding their incision healing and recovery from surgery at the 6-month
      follow-up visit.

      The primary objective of this study is to assess the feasibility of a full RCT comparing
      perioperative outcomes in patients undergoing robotic vs. open partial nephrectomy at the
      investigator's institution.

      The secondary objective of the study is to compare pilot outcome measures addressing
      oncologic, functional, and health economics outcomes to assess whether a full RCT is
      worthwhile and feasible.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment Potential</measure>
    <time_frame>Study duration (2 years)</time_frame>
    <description>Rate of accrual [participants per month]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suitability of secondary outcome measures</measure>
    <time_frame>Study duration (2 years)</time_frame>
    <description>Assess the feasibility of collecting all secondary outcome data. To be assessed qualitatively by the study team and by calculating the proportion of patients with each data point completed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resource Utilization - Operating Room/Robotic Studio Time Availability</measure>
    <time_frame>Study duration (2 years)</time_frame>
    <description>Assess the capacity of accommodating surgical time for a full scale clinical trial. Measured by time from decision to treat to surgery date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resource Utilization - Cost of Study Participation</measure>
    <time_frame>Study duration (2 years)</time_frame>
    <description>To develop an accurate budget for a full trail, we are assessing the average cost of running the trial per patient, per arm. This calculation will include: cost of study coordinator time (number of hours x hourly wage), additional cost of robotic disposables, and cost of additional testing outside of standard of care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative Time</measure>
    <time_frame>Duration of surgery</time_frame>
    <description>Operative time in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Warm Ischemia Time</measure>
    <time_frame>Duration of surgery</time_frame>
    <description>Measured in minutes from the time of application of first vascular clamp to removal of clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>Duration of surgery</time_frame>
    <description>Estimated blood loss (mL), transfusion rates, use of hemostatic agents (which agents and how many used)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate to radical nephrectomy or open partial nephrectomy</measure>
    <time_frame>Duration of surgery</time_frame>
    <description>Time in minutes from the start of robotic partial nephrectomy to the time decision was made to convert</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>1-7 days</time_frame>
    <description>Calculated from day of admission to day of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication Rates</measure>
    <time_frame>Up to 6 months post-surgery</time_frame>
    <description>Clavien-Dindo classification and need for/extent of re-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>Up to 6 months post-surgery</time_frame>
    <description>Creatinine and eGFR measured pre-op, day 1 post-op, 4-7 weeks post-op, 6 months post-op</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive margin rate</measure>
    <time_frame>1-3 weeks post-operatively</time_frame>
    <description>Frequency of positive margins as reported in the final pathology report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Margin size</measure>
    <time_frame>1-3 weeks post-operatively</time_frame>
    <description>Distance from tumour to surgical margin (mm) as reported in final pathology report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic Requirements</measure>
    <time_frame>Up to 6 months post-operatively</time_frame>
    <description>use of epidural, PCA, or oral analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: EORTC QLQ-C30</measure>
    <time_frame>Up to 6 months post-operatively</time_frame>
    <description>Measured using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at 4-7 weeks and 6 months post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Recovery/Flank Bulge</measure>
    <time_frame>6 months from surgical date</time_frame>
    <description>Surveyed at 6 months post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economics</measure>
    <time_frame>Study duration (2 years)</time_frame>
    <description>Estimated overall cost of surgery for each arm (surgical supplies, length of stay, etc.) and cost of post-operative readmissions and ER visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Masses</condition>
  <arm_group>
    <arm_group_label>Robotic Partial Nephrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Partial nephrectomy performed using the DaVinci robotic surgical system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Partial Nephrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Partial nephrectomy performed using the open approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic Partial Nephrectomy</intervention_name>
    <description>Robotic partial nephrectomy using da Vinci robot.</description>
    <arm_group_label>Robotic Partial Nephrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open Partial Nephrectomy</intervention_name>
    <description>Standard open partial nephrectomy</description>
    <arm_group_label>Open Partial Nephrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radiologically characterized T1 renal mass

          -  Elected for partial nephrectomy surgery

          -  Under the care of a uro-oncologist at Princess Margaret Cancer Centre

          -  Willing to comply with follow-up protocol

          -  Capable of providing informed consent

        Exclusion Criteria:

          -  Radiologically characterized tumours â‰¥ T1

          -  Unfit for general anesthetic

          -  Unsuitable for robotic surgery (determined by treating physician)

          -  Unwilling to comply with standardized follow-up protocol

          -  Evidence of metastatic disease

          -  Solitary kidney

          -  Previous surgery on affected kidney

          -  Multiple tumours

          -  Known genetic syndromes predisposing to multiple renal tumours (e.g., VHL, TS, BHD)

          -  Pregnancy

          -  Inability to read, understand, and complete the questionnaires written in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Hamilton, MD</last_name>
    <phone>416-946-2909</phone>
    <email>rob.hamilton@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Landoni, MSc</last_name>
    <phone>416-946-2282</phone>
    <email>lauren.landoni@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minimally Invasive Surgery</keyword>
  <keyword>Robotic Surgery</keyword>
  <keyword>Partial Nephrectomy</keyword>
  <keyword>Feasibility</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

